<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027568</url>
  </required_header>
  <id_info>
    <org_study_id>IOA-289</org_study_id>
    <nct_id>NCT05027568</nct_id>
  </id_info>
  <brief_title>A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of IOA-289 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOnctura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOnctura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability&#xD;
      after single ascending oral doses of IOA-289 given to healthy male subjects, compared to&#xD;
      placebo. After the oral dose administrations, the amount of IOA-289 present in serum will be&#xD;
      determined for pharmacokinetic characterisation. Also the reduction of LPA in plasma will be&#xD;
      determined as a pharmacodynamic biomarker.&#xD;
&#xD;
      Part 2 is optional and its conduct will be dependent on the pharmacokinetic data generated in&#xD;
      Part 1. Part 2 will be a randomized, crossover, open label, single oral dose administration&#xD;
      of IOA-289 to healthy male subjects either in a fasted state, or after a high-fat meal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of participants with treatment-related adverse events as assessed by MedDRA v24</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>Adverse Events will be assessed by nondirective questioning of the participants during the screening process and at each visit during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of IOA-289</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>Blood samples for plasma IOA-289 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>The maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>The time at which Cmax occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>The area under the plasma concentration-time curve from time of dosing to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the change from baseline of LPA levels</measure>
    <time_frame>Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose</time_frame>
    <description>Measurement of LPA levels in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Drug: IOA-289 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of IOA-289 liquid filled capsule formulation - ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo liquid filled caspule formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single ascending doses of IOA-289</intervention_name>
    <description>Single dose, oral administration of liquid-filled capsules, with a starting dose of 30 mg</description>
    <arm_group_label>Drug: IOA-289 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single doses</intervention_name>
    <description>Single dose, oral administration of liquid-filled capsules, matching placebo</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects between 18 and 50 years of age (inclusive) at the screening&#xD;
             visit&#xD;
&#xD;
          -  Body mass index between 18.0 and 30.0 kg/m2 (inclusive) at the screening visit&#xD;
&#xD;
          -  In good health as determined by medical history, physical examination, ECG,&#xD;
             serum/urine, clinical chemistry, haematology, and serology tests&#xD;
&#xD;
          -  Able to provide written, informed consent prior to initiation of any trial-related&#xD;
             procedures, and able, in the opinion of the Principal Investigator, to comply with all&#xD;
             the requirements of the trial&#xD;
&#xD;
          -  Male subjects who are surgically sterile (i.e., have undergone bilateral&#xD;
             orchidectomy); and male subjects who agree to remain abstinent or to practice&#xD;
             double-barrier forms of birth control and refrain from sperm donation from trial&#xD;
             screening through 90 days from the last dose of IMP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormality in past medical history, or at the screening&#xD;
             physical examination, that in the Investigator's or Sponsor's opinion may place the&#xD;
             subject at risk or interfere with outcome variables including absorption,&#xD;
             distribution, metabolism, and excretion of IMP&#xD;
&#xD;
          -  History of drug and/or alcohol abuse within 2 years prior to the screening visit&#xD;
&#xD;
          -  History of or current hepatitis or acquired immunodeficiency syndrome or carriers of&#xD;
             HBsAg, anti-HCV, and/or HIV antibodies&#xD;
&#xD;
          -  History of any significant drug allergy&#xD;
&#xD;
          -  Positive alcohol breath test and/or urine drug screen for substance of abuse at the&#xD;
             screening visit or upon check-in to the clinical trial site&#xD;
&#xD;
          -  History of having taken an investigational drug within 30 days preceding trial entry&#xD;
&#xD;
          -  History of significant bleeding or haemorrhagic tendencies&#xD;
&#xD;
          -  Donation of blood or plasma within 30 days prior to dosing&#xD;
&#xD;
          -  Use of prescription medication, over-the-counter medication, herbal medication, or&#xD;
             vitamin supplements within 14 days prior to dosing and antibiotics within 30 days&#xD;
             prior to dosing. The Sponsor may allow exceptions only if the medication's&#xD;
             administration is deemed unlikely to impact the PK result&#xD;
&#xD;
          -  Exposure to any substances known to stimulate hepatic microsomal enzymes within 30&#xD;
             days prior to screening (e.g., occupational exposure to pesticides, organic solvents)&#xD;
&#xD;
          -  Supine blood pressure, after resting for ≥3 minutes, higher than 140/90 mmHg or lower&#xD;
             than 100/50 mmHg. The Sponsor may allow exceptions if they are not deemed clinically&#xD;
             significant&#xD;
&#xD;
          -  Supine pulse rate, after resting for ≥3 minutes, outside the range of 50 to 90 bpm.&#xD;
             The Sponsor may allow exceptions if they are not deemed clinically significant&#xD;
&#xD;
          -  History of serious mental disorders that, in the opinion of the Investigator, would&#xD;
             exclude the subject from participating in this trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Lahn, MD</last_name>
    <phone>+41795066366</phone>
    <email>m.lahn@ionctura.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Ricerche Cliniche di Verona srl</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Milleri, MD, PhD</last_name>
      <phone>+39 0458126618</phone>
      <email>stefano.milleri@crc.vr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

